Intensity Therapeutics Q2 EPS $(1.11), Inline
Intensity Therapeutics (NASDAQ:INTS) reported quarterly losses of $(1.11) per share which met the analyst consensus estimate. This is a 66.96 percent increase over losses of $(3.36) per share from the same period last
Intensity Therapeutics lost less money per share than it did a year ago, which is exactly what experts predicted. When a company that's still losing money actually loses *less*, it hints the company might be moving toward making money someday.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.